Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
Intranasal Delivery of SPC-15 shows rapid and effective drug exposure for PTSD Therapy
SARASOTA, FL, April 23, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq:SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced positive data in the final validation report from the recent pharmacokinetic (PK) study